On October 29, pku healthcare corp. (000788.SZ) announced that recently, pku healthcare corp. received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Paroxetine Hydrochloride Enteric-Coated Prolonged-Release Tablets.
Paroxetine Hydrochloride Enteric-Coated Prolonged-Release Tablets (hereinafter referred to as "Paroxetine Enteric-Coated Prolonged-Release Tablets") is a potent, highly selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the synaptic cleft, enhances central serotonin neurotransmission, and improves depressive symptoms. Currently, paroxetine is recommended as first-line therapy for depression in multiple domestic and international treatment guidelines. Compared with ordinary tablets, Paroxetine Enteric-Coated Prolonged-Release Tablets can slow down the release rate of the drug in the gastrointestinal tract, reduce the peak-to-trough ratio of blood drug concentration, thereby reducing adverse reactions, improving patient compliance, and thus has higher medical value.
